Highlights Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-06-06 pm EDT			5-day change	1st Jan Change
146.4 ^USD	+0.31%		+0.78%	-6.58%

01:51am	J&J-backed Rapport Therapeutics raises $136 mln in US IPO	RE
Jun. 06	Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

J&J-backed Rapport Therapeutics raises $136 mln in US IPO	07:51pm	RE
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	Jun. 04
J&J: successful trial for Carvykti in multiple myeloma	Jun. 04	CF
J&J: promising trial for Tecvayli in multiple myeloma	Jun. 04	CF
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	Jun. 04	MT
J&J must pay $260 million in latest talc trial, Oregon jury says	Jun. 03	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	Jun. 03	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	Jun. 03	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	Jun. 03	CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	Jun. 03	CI
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	Jun. 03	CI
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	Jun. 03	RE
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	Jun. 03	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02	RE
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	May. 31	CI
Sector Update: Health Care Stocks Higher Late Afternoon	May. 31	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	May. 31	MT
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	May. 31	MT
J&J: completes acquisition of Shockwave Medical	May. 31	CF
Johnson & Johnson Closes Acquisition of Shockwave Medical	May. 31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST